Pharma Nostra

pharmanostra.com.br

A Pharma Nostra® é uma empresa científica, voltada para a pesquisa e desenvolvimento, que tem como carro-chefe a inovação, qualidade e comprometimento com o setor magistral. Durante a sua trajetória, a Pharma Nostra® consolidou-se como especialista no tratamento individualizado, isso porque a marca compreende cada ser humano como único e, com base em suas necessidades específicas, permite tornar qualquer fórmula sob medida e multidisciplinar.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

TRANSACTION DATA SYSTEMS ACHIEVES KLOUDSCRIPT, A CLOUD-BASED SPECIALTY PHARMACY SOLUTION

Transaction Data Systems | November 25, 2020

news image

Exchange Data Systems (TDS), the pioneer in drug store programming answers for the network drug store market, today reported the obtaining of KloudScript, a strength drug store care arrangement. Right now 39% of network drug stores apportion a type of strength prescriptions, agreeing the National Community Pharmacy Association. Interest for strength meds has been consistently ascending to treat explicit sickness states and the constantly sick. With the maturing populace and the ex...

Read More

Business Insights, PHARMACY MARKET

PHIO PHARMACEUTICALS ANNOUNCES NEW CLINICAL PROGRAM TO STUDY PH-762 FOR THE TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA

Phio Pharmaceuticals Corp. | December 22, 2022

news image

Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762. Phio is a clinical stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intrat...

Read More

Business Insights

POSTERA SPEARHEADS AI-DRIVEN DRUG DISCOVERY COLLABORATION TO DEVELOP ANTIVIRAL THERAPEUTICS WITH INITIAL $68M IN NIH FUNDING

PostEra | May 19, 2022

news image

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The center will receive initial funding of $68M. PostEra co-leads this initiative with the Drugs for Neglected Diseases Initiative, a global charity with expertise in drug development for global equitable access, and the Memorial Sloan Kettering Cancer Ce...

Read More

Business Insights

MISSION BIO ANNOUNCES PHARMA ASSAY DEVELOPMENT SERVICES FOR SOLID TUMOR RESEARCH

Mission Bio | July 13, 2022

news image

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challenges a...

Read More
news image

Pharmacy Market

TRANSACTION DATA SYSTEMS ACHIEVES KLOUDSCRIPT, A CLOUD-BASED SPECIALTY PHARMACY SOLUTION

Transaction Data Systems | November 25, 2020

Exchange Data Systems (TDS), the pioneer in drug store programming answers for the network drug store market, today reported the obtaining of KloudScript, a strength drug store care arrangement. Right now 39% of network drug stores apportion a type of strength prescriptions, agreeing the National Community Pharmacy Association. Interest for strength meds has been consistently ascending to treat explicit sickness states and the constantly sick. With the maturing populace and the ex...

Read More
news image

Business Insights, PHARMACY MARKET

PHIO PHARMACEUTICALS ANNOUNCES NEW CLINICAL PROGRAM TO STUDY PH-762 FOR THE TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA

Phio Pharmaceuticals Corp. | December 22, 2022

Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL™ compound, PH-762. Phio is a clinical stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intrat...

Read More
news image

Business Insights

POSTERA SPEARHEADS AI-DRIVEN DRUG DISCOVERY COLLABORATION TO DEVELOP ANTIVIRAL THERAPEUTICS WITH INITIAL $68M IN NIH FUNDING

PostEra | May 19, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The center will receive initial funding of $68M. PostEra co-leads this initiative with the Drugs for Neglected Diseases Initiative, a global charity with expertise in drug development for global equitable access, and the Memorial Sloan Kettering Cancer Ce...

Read More
news image

Business Insights

MISSION BIO ANNOUNCES PHARMA ASSAY DEVELOPMENT SERVICES FOR SOLID TUMOR RESEARCH

Mission Bio | July 13, 2022

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challenges a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us